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Abstract
Background: The relative importance of human diseases is conventionally assessed by cause-specific mortality, morbidity,
and economic impact. Current estimates for infections caused by antibiotic-resistant bacteria are not sufficiently supported
by quantitative empirical data. This study determined the excess number of deaths, bed-days, and hospital costs associated
with blood stream infections (BSIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) and third-generation
cephalosporin-resistant Escherichia coli (G3CREC) in 31 countries that participated in the European Antimicrobial Resistance
Surveillance System (EARSS).
Methods and Findings: The number of BSIs caused by MRSA and G3CREC was extrapolated from EARSS prevalence data
and national health care statistics. Prospective cohort studies, carried out in hospitals participating in EARSS in 2007,
provided the parameters for estimating the excess 30-d mortality and hospital stay associated with BSIs caused by either
MRSA or G3CREC. Hospital expenditure was derived from a publicly available cost model. Trends established by EARSS were
used to determine the trajectories for MRSA and G3CREC prevalence until 2015. In 2007, 27,711 episodes of MRSA BSIs were
associated with 5,503 excess deaths and 255,683 excess hospital days in the participating countries, whereas 15,183
episodes of G3CREC BSIs were associated with 2,712 excess deaths and 120,065 extra hospital days. The total costs
attributable to excess hospital stays for MRSA and G3CREC BSIs were 44.0 and 18.1 million Euros (63.1 and 29.7 million
international dollars), respectively. Based on prevailing trends, the number of BSIs caused by G3CREC is likely to rapidly
increase, outnumbering the number of MRSA BSIs in the near future.
Conclusions: Excess mortality associated with BSIs caused by MRSA and G3CREC is significant, and the prolongation of
hospital stay imposes a considerable burden on health care systems. A foreseeable shift in the burden of antibiotic
resistance from Gram-positive to Gram-negative infections will exacerbate this situation and is reason for concern.
Please see later in the article for the Editors’ Summary.
Citation: de Kraker MEA, Davey PG, Grundmann H, on behalf of the BURDEN study group (2011) Mortality and Hospital Stay Associated with Resistant
Staphylococcus aureus and Escherichia coli Bacteremia: Estimating the Burden of Antibiotic Resistance in Europe. PLoS Med 8(10): e1001104. doi:10.1371/
journal.pmed.1001104
Academic Editor: Steven M. Opal, Brown University School of Medicine, United States of America
Received December 10, 2010; Accepted August 24, 2011; Published October 11, 2011
Copyright:  2011 de Kraker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by DG-Sanco (grant number 2005203), University Medical Centre Groningen, and the Netherlands National Institute for Public
Health and the Environment. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: All authors have read the journal’s policy and HG and MdK have declared that they have no competing interests. PD has the following
conflicts, he has received support for research projects about the management of infection from Janssen Cilag and about the epidemiology of asthma from Glaxo
Smith Kline. He has been a member of an Advisory Board on antimicrobial resistance for Wyeth and an Advisory Board about new antibiotics for Johnson and
Johnson. He has received speaker fees and support to attend meetings from Johnson & Johnson and Optimer Pharmaceuticals.
Abbreviations: AMR, antimicrobial resistance; BoD, burden of disease; BSI, blood stream infection; BURDEN, Burden of Resistance and Disease in European
Nations; CI95, 95% confidence interval; EARSS, European Antimicrobial Resistance Surveillance System; EFTA, European Free Trade Association; G3CREC, third-
generation cephalosporin-resistant Escherichia coli; G3SEC, third-generation cephalosporin-susceptible E. coli; MRSA, methicillin-resistant Staphylococcus aureus;
MSSA, methicillin-susceptible Staphylococcus aureus
* E-mail: marlieke.de.kraker@rivm.nl
PLoS Medicine | www.plosmedicine.org 1 October 2011 | Volume 8 | Issue 10 | e1001104Introduction
Managing increasingly limited resources is one of the key
challenges in contemporary health care. Although antibiotic
resistance is threatening the success of medical services, the exact
societal implications have not been adequately quantified. In order
to inform the public health debate in Europe and beyond, reliable
estimates about excess mortality, morbidity, and costs are
imperative. Data about this burden of disease (BoD) will enable
evaluation of antimicrobial resistance (AMR) against other
competing causes of morbidity and mortality. Moreover, medi-
um-term trends can shed light on expected health care demands in
the near future. Hitherto such information has not been available
because of the absence of representative empirical data.
Recently, clinical studies carried out under the remit of the
Burden of Resistance and Disease in European Nations (BUR-
DEN) project [1] filled this void. Within the BURDEN
framework, we estimated the impact of antibiotic resistance
associated with the two most frequent causes of blood stream
infections (BSIs) worldwide—Staphylococcus aureus and Escherichia coli
[2]. For these pathogens we focused on two of the most clinically
relevant resistance phenotypes—methicillin (meticillin) resistance
for S. aureus and third-generation cephalosporin resistance for E.
coli. Both phenotypes are typically associated with resistance to
multiple classes of antibiotics and can be regarded as surrogate
markers for multi-drug resistance. During these studies the clinical
outcome and excess hospital stay for infected patients in 13
different hospitals in as many different European countries were
prospectively ascertained [3,4].
Here we provide estimates on the BoD of resistance by
combining these results with prevalence data from the European
Antibiotic Resistance Surveillance System (EARSS). EARSS data
were collected under the supervision of two of the authors (H. G.
and M. E. A. d. K.) at the Netherlands’ National Institute for
Public Health and the Environment between 1999 and 2009. We
report excess mortality, excess hospital stay, and the related
hospital expenditure associated with methicillin-resistant S. aureus
(MRSA) and third-generation cephalosporin-resistant E. coli
(G3CREC) bacteremias, and provide trend-based trajectories
until 2015 for all countries that participated in EARSS in 2007.
Methods
Analyses focused on episodes of MSRA and methicillin-
susceptible S. aureus (MSSA), as well as G3CREC and third-
generation cephalosporin-susceptible E. coli (G3SEC) BSIs report-
ed to EARSS in 2007. In that year, 31 countries participated in
EARSS, consisting of all European Union member states
(excluding Slovakia), the two EU candidate countries (Croatia
and Turkey), two European Free Trade Association (EFTA)
countries (Norway and Iceland), and Israel, henceforth referred to
as the European region. Susceptibility was determined according
to consensus protocols published in the EARSS manual [5].
Number and Incidence of Events
Since all diagnostic microbiological laboratories in Estonia,
Hungary, Iceland, Ireland, Luxembourg, Malta, and Slovenia
reported to EARSS (100% coverage), the total number of BSIs
could be directly extracted from the EARSS database for these
countries [6]. For the UK, the total number of BSIs caused by S.
aureus (MRSA and MSSA) was provided by the Health Protection
Agency, the Health Protection Scotland, the Welsh Healthcare
Associated Infection Programme, and the Public Health Agency
Northern Ireland through their mandatory reporting schemes.
Data for the UK for E. coli (G3CREC and G3CSEC) were
extracted from these programs’ voluntary reporting schemes.
For all other countries, the expected total number of events was
based on the number of bacteremias and hospital beds in the
EARSS sample, combined with the total volume of acute care
beds per country. National volume data was obtained from the
online Eurostat database [7], the Organisation for Economic Co-
operation and Development Health Data 2010 database [8], or
provided by national institutes for public health (see Table S1 and
Acknowledgments). Through the svyglm function in the R package
‘‘survey,’’ the odds of a BSI case per bed, including a 95%
confidence interval (CI95), was estimated per BSI type and
country. This method fits a generalized linear model with a quasi
binomial distribution and logit link function. It accounts for the
cluster effect (of sampling within countries) and finite populations
(national volume of acute care beds). The model-derived odds,
including CI95, were transformed to proportion (P) and then
multiplied with the national volume of acute care beds to derive
country-specific estimates for the total number of bacteremias
(#BSIs). Resulting CI95 were smaller for countries with higher
national EARSS coverage. Incidence was calculated by dividing
these estimates, including the CI95, by population census data
taken from the World Health Organization database [9].
Excess Deaths, Bed-Days, and Costs
Adjusted odds ratios (aOR) for 30-d mortality, mortality
proportions for the control group without S. aureus or E. coli
bacteremia (P0), and excess length of stay in days (LOSR) were
obtained from the clinical outcome studies described previously
(Table S2) [3,4]. The excess number of deaths (D) and extra bed-
days (B) associated with BSIs caused by MRSA, MSSA, G3CREC,
and G3CSEC were then calculated for each country, using
Equation 1, derived from Bender and Blettner [10], and Equation
2, respectively:
D~
#BSIs   P0   (aOR{1)   (1{P0)
aOR   P0z(1{P0)
ð1Þ
B~#BSIs   LOSR ð2Þ
To determine CI95 for D and B, we used parametric
bootstrapping. We sampled 10,000 simulations from the distribu-
tion for the log-odds of P, the log-odds of aOR, and the log-
duration of LOSR. Thereafter, D and B were calculated for these
sampled values, and CI95 could be based on the 2.5% and 97.5%
quantiles from the resulting distributions. In this way, the CI95
included the uncertainty in the estimated number of bacteremias
as well as the uncertainty in aOR and LOSR. As a result, CI95
were wider for countries with a low EARSS hospital participation
ratio, and for BoD estimates for G3CREC compared to MRSA,
because of wider confidence intervals for the clinical outcome
measures for G3CREC (Table S2).
Excess hospital expenditure, including CI95, was based on the
product of the excess number of bed-days and country-specific
unit costs per hospital day. These hotel costs were derived from the
WHO-CHOICE model [11,12], and do not entail extra costs for
procedures or treatments associated with antibiotic-resistant
infections. The model-derived costs in local currency units of
2005 were indexed by country-specific consumer price indices
[13–16] to approach costs in 2007. Hereafter these amounts were
converted into Euros using historical exchange rates [17] and into
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Resistance Trajectories until 2015
The trajectories for BSIs caused by MRSA and G3CREC in the
European region were based on trends in overall incidence of S.
aureus and E. coli BSIs and changes in the relative proportions of
MRSA and G3CREC as reported to EARSS. Data were extracted
for all laboratories that consistently reported susceptibility results
for S. aureus (1 January 2001–31 December 2009) and E. coli
(1 January 2003–31 December 2009). The final results were
generated in a multi-step procedure. First, the secular trends in the
absolute number of E. coli and S. aureus BSIs until 2015 were
obtained by linear regression. Second, the rate change in the
proportions of BSIs with methicillin resistance and third-
generation cephalosporin resistance was modeled by logistic
regression [18]. In both models, year was included as a (log)linear
independent variable. Higher order terms of time were included
on the basis of the F-statistic and the likelihood ratio test (p,0.05).
Model fit was assessed by the F- and Hosmer-Lemeshow statistic.
The product of the two trends provided the crude trajectory for
MRSA and G3CREC BSIs until 2015 for the sample of
laboratories that consistently reported to EARSS. Finally, this
trajectory was normalized against the reference incidence
ascertained for 2007 and scaled to the total number of MRSA
and G3CREC BSIs in the European region on the basis of total
event estimates for 2007 (#BSIs) described above. All analyses
were carried out using R 2.8.1 or SAS 9.2.
The Medical Ethics Committee of the University Medical
Centre Utrecht waived ethical clearance for this study.
Results
Burden of Resistance
In 2007, 1,293 hospitals from 31 countries reported antimicro-
bial susceptibility test results for S. aureus and E. coli causing BSIs to
the EARSS database [6]. At the national level, surveillance
covered over 47% of all available acute care hospital beds for most
countries (interquartile range 12%–99%). Altogether, susceptibility
results for 18,000 S. aureus and 28,024 E. coli blood stream isolates
were reported in 2007.
For S. aureus, the estimated number of BSIs in the European
region totaled 108,434 (CI95 103,637–112,948), of these, 27,711
(25.6%) were methicillin-resistant (range 0% in Iceland to 52% in
Malta). E. coli caused 163,476 (CI95 157,891–168,624) BSIs, of
which 15,183 (9.3%) were resistant to third-generation cephalo-
sporins (range 2% in Iceland to 40% in Turkey). The incidence of
MRSA ranged from zero in Iceland and Norway to 18.7/100,000
(CI95 17.6–19.9) in Portugal, and for G3CREC from 0.1 (reported
number, no confidence interval) in Estonia to 8.1 (CI95 7.0–9.2) in
Israel (Table 1).
In the same year, an estimated 5,503 (CI95 3,136–8,267) excess
deaths were associated with BSIs caused by MRSA and 2,712
(CI95 595–5,780) with BSIs caused by G3CREC, based on risk
estimates from previous clinical outcome studies (Table S2) [3,4].
In 2007, the UK and France predictably experienced the highest
excess mortality associated with BSIs caused by MRSA, with 1,096
(CI95 627–1,650) and 898 (CI95 511–1,364) fatalities, respectively.
For BSIs caused by G3CREC, excess mortality was predicted to
be the highest in Turkey (793, CI95 178–1,716) and the UK (504,
CI95 114–1,078) and lowest in Iceland (1, CI95 0–2) and Estonia
(0, CI95 0–1) (Table S3).
At the same time, BSIs caused by MRSA and G3CREC
contributed an excess of 255,683 (CI95 142,934–375,880) and
120,065 (CI95 52,272–198,338) extra bed-days. This excess length
of hospital stay accounted for an estimated extra cost of 62.0
million Euros (CI95 31.4–100.0 million), equivalent to 92.8 million
international dollars (CI95 47.0–149.0 million) in 2007 (Table S4).
Trends and Future Trajectories
For S. aureus, 266 laboratories serving 810 hospitals in
25 countries consistently reported antibiotic susceptibility test
results to the EARSS database between 1 January 2001 and 31
December 2009, totaling 121,469 blood isolates. During the same
period, the absolute number of reported S. aureus BSIs increased
from 10,874 to 15,299. Methicillin resistance increased from
19.1% in 2001 to 22.6% in 2005 and then decreased to 18.0% by
2009 (Figure S1).
For E. coli, 281 laboratories serving 791 hospitals in 28 countries
consistently reported antimicrobial susceptibility (136,217 blood
isolates) between 1 January 2003 and 31 December 2009. During
this time, the number of E. coli BSIs increased from 19,332 to
29,938. Resistance to G3CEP increased from 2.7% in 2003 to
8.2% in 2009 (Figure S2).
Figure 1 shows that, based on the relative trends from EARSS,
the number of G3CREC bacteremias is likely to surpass the
number of MRSA bacteremias in the near future. As a result, the
additive burden of G3CREC and MRSA bacteremias in the
European region will increase. If current trends prevail, the
trajectories suggest that about 97,000 resistant BSIs and 17,000
associated fatalities could be expected in 2015. Hospital stay and
expenditure would likewise increase.
Discussion
By combining representative data on clinical outcome with
population-based incidence figures, we estimated that more than
8,000 deaths and 62 million Euros in excess costs were associated
with MRSA and G3CREC BSIs in the European region in 2007.
To our knowledge, this is the first quantification of the BoD for
antibiotic resistance in this region based on empirical data.
As early as 1998, an EU conference titled ‘‘The Microbial
Threat’’ in Visby, Denmark, emphasized that the most important
questions regarding increasing resistance concern the potential
rise in morbidity, mortality, and costs [19]. Although more insight
into the prevalence of antibiotic resistance has been gained
[20–23], its overall effect on human health and societies remained
to be defined. With some notable exceptions such as TB, HIV,
malaria and gonorrhea, most of the disease burden attributable to
AMR is caused by hospital-associated infections due to opportu-
nistic bacterial pathogens. These often cause life-threatening or
difficult-to-manage conditions such as deep tissue, wound, or bone
infections or infections of the lower respiratory tract, central
nervous system, or the bloodstream. We chose to investigate the
BoD associated with AMR in BSIs. This decision was guided by
the clinical importance of BSIs and the fact that prevalence data
are available from one of the largest international surveillance
systems (EARSS), recording antibiotic resistance for more than
1,400 European hospitals.
This study took advantage of recently published observational
studies [3,4]. These were purposely designed to provide an
objective measure about excess mortality and length of hospital
stay associated with MRSA and G3CREC BSIs for Europe. In
addition, these studies took into account that MRSA and
G3CREC bacteremias add to, rather than replace, the BoD
caused by their susceptible counterparts [24–28]. To this effect,
clinical outcome measures of patients with resistant as well as
susceptible BSIs were compared to those of uninfected controls.
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need to be considered. First, a potential source of bias is inherent
to the surveillance data from EARSS. Second, bias may have been
introduced through the clinical outcome measures from the
BURDEN studies. Finally, effect modification due to varying levels
of appropriate empirical treatment could have influenced our
results.
The incidence of resistant BSIs reported by EARSS hospitals
may differ from the national average, because of the size, different
standards of care, and/or different local epidemiology of EARSS
hospitals [29,30]. This limitation in representativeness, however,
only applies to a minority of countries. In 2007, ten of the EARSS
national networks collected complete data for all acute care
hospitals in these countries, a further 11 networks had coverage
above 50% [6]. Incidence data from alternative sources, such as
the BMR-Raisin network in France [31] and nationwide
registration of S. aureus BSIs in Denmark [32], underline the
representativeness of our estimates for these countries. However,
for Germany, Italy, and Greece, where EARSS population
coverage was below 20%, the estimated incidence may be less
reliable. The direction of this potential bias is not easily
predictable. In the case of Germany, where mandatory reporting
for MRSA bacteremia started in 2009, data indicate that our
model may have underestimated the true burden [33].
Compared to the clinical outcome studies that provided the
baseline for the current investigation [3,4], other recent, well-
designed studies came to more conservative estimates for the
clinical impact of MRSA [34,35]. However, differences in study
design and outcome measures make direct comparisons difficult;
presented hazard ratios [34,35] cannot be directly compared with
odds ratios [3,4]. Moreover, Wolkewitz et al. [34] focused on a
single center, while Lambert et al. [35] observed outcomes of
patients during their stay in intensive care units. Estimates used in
the present study were based on 30-d follow-up in multiple centers
from different European countries. This provided better compre-
hensiveness and consequently bears more relevance to the BoD
estimates for acute care for Europe as a whole.
Finally, the current analysis did not consider the impact of a
delay in appropriate therapy. This may have had a negative effect
on clinical outcome. However, considering that ineffective
empirical therapy is often a direct consequence of antibiotic
resistance, we did not separate this effect from our analysis as we
regard it as an integral part of the burden caused by resistance.
Using empirical data improved the validity of our estimates of
the impact of antibiotic resistance in the European region.
However, limiting our study to BSIs caused by two, albeit
important, pathogens ignores the consequences of antibiotic
resistance due to infections of other causes and at other anatomical
sites. More work is therefore required to fathom the total
magnitude of antibiotic resistance as a public health issue. A
recent report from the European Centre for Disease Control [36]
also estimated the human and economic BoD of antibiotic
resistance in Europe. This report included six of the bacterial
pathogens under surveillance by EARSS and, in addition to BSIs,
included four other types of infections: pneumonia, and abdom-
inal, urinary tract, and soft tissue infections. It should be noted that
these estimates must be used with caution for several reasons.
Country-specific incidence estimates for BSIs were extrapolated
from self-reported national catchment populations, an approach
which frequently overestimates EARSS coverage [6]. In addition,
BoD estimates were mainly based on risk data from small, single
center studies. At the same time, questionable assumptions were
necessary to estimate the incidence and BoD for infections at other
anatomical sites based on estimates for BSIs.
Even when considering these restrictions, our results suggest
that mortality attributed to AMR is considerable, but not excessive
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Figure 1. Trends in the estimated number of MRSA and G3CREC bacteremias in the European region. Extrapolated EARSS numbers for
2003–2009, and future trajectories based on regression analysis for 2010–2015.
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PLoS Medicine | www.plosmedicine.org 5 October 2011 | Volume 8 | Issue 10 | e1001104when compared to other causes. For high income countries in
Europe, including 21 of 31 participating in EARSS, the World
Health Organization reports that the highest number of deaths is
associated with cardiovascular disorders (373 deaths per 100,000)
[37]. Among communicable diseases, lower respiratory tract
infections (29.5 per 100,000) rank highest [37]. For G3REC and
MRSA BSIs, the estimated mortality (1.5 per 100,000 in the high
income countries) is on par with rates for HIV/AIDS (1.5 per
100,000) or tuberculosis (1.0 per 100,000) [37].
How will this change in the near future? Here, we project that
the combined burden of resistance of MRSA and G3CREC will
be growing, leading to a predicted incidence of 3.3 associated
deaths per 100,000 inhabitants in 2015. The burden of resistance
will thereby likely surpass the current estimates for casualties
associated with, for example, cervical cancer (2.7 per 100,000)
[37]. Although these presented forecasts emphasize the increasing
importance of resistance, especially for third-generation cephalo-
sporin resistance in E. coli BSIs, these predictions should be
interpreted with caution. The presented trajectories were based on
a continuation of current trends, reflecting the unlikely scenario
that saturation effects of present control efforts [38] or expansion
of newly emerging clones or resistance mechanisms [39,40] will
not take place. Since these events are highly unpredictable, they
may thwart attempts towards reliable trend analysis.
We conclude that excess mortality associated with MRSA and
G3CREC is high, even though it represents only a fraction of the
total BoD associated with antibiotic resistance. Forecasts about
changes in the coming years are disturbing; despite anticipated gains
in the control of MRSA, the persistently increasing number of
infections caused by third-generation cephalosporin-resistant Gram-
negative pathogens is likely to outweigh this achievement soon.
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Background. Antimicrobial resistance—a consequence of
theuseandmisuseofantimicrobialmedicines—occurswhena
microorganism becomes resistant (usually by mutation or
acquiring a resistance gene) to an antimicrobial drug to which
it was previously sensitive. Then standard treatments become
ineffective, leading to persistent infections, which may spread
to other people. With some notable exceptions such as TB,
HIV, malaria, and gonorrhea, most of the disease burden
attributable to antimicrobial resistance is caused by hospital-
associatedinfectionsduetoopportunisticbacterialpathogens.
These bacteria often cause life-threatening or difficult-to-
manage conditions such as deep tissue, wound, or bone
infections, or infections of the lower respiratory tract, central
nervous system, or blood stream. The two most frequent
causes of blood stream infections encountered worldwide are
Staphylococcus aureus and Escherichia coli.
Why Was This Study Done? Although hospital-associated
infections have gained much attention over the past decade,
the overall effect of this growing phenomenon on human
health and medical services has still to be adequately
quantified. The researchers proposed to fill this information
gap by estimating the impact—morbidity, mortality, and
demands on health care services—of antibiotic resistance in
Europe for two types of resistant organisms that are typically
associated with resistance to multiple classes of antibiotics
and can be regarded as surrogate markers for multi-drug
resistance—methicillin-resistant S. aureus and third-generation
cephalosporin-resistant E. coli.
What Did the Researchers Do and Find? Recently, the
Burden of Resistance and Disease in European Nations
project collected representative data on the clinical impact
of antimicrobial resistance throughout Europe. Using and
combining this information with 2007 prevalence data
from the European Antibiotic Resistance Surveillance
System, the researchers calculated the burden of disease
associated with methicillin-resistant S. aureus and third-
generation cephalosporin-resistant E. coli blood stream
infections. This burden of disease was expressed as excess
number of deaths, excess number of days in hospital, and
excess costs. Using statistical models, the researchers
predicted trend-based resistance trajectories up to 2015 for
the 31 participating countries in the European region.
The researchers included 1,293 hospitals from the 31
countries, typically covering 47% of all available acute care
hospital beds in most countries, in their analysis. For S. aureus,
the estimated number of blood stream infections totaled
108,434, of which 27,711 (25.6%) were methicillin-resistant. E.
coli caused 163,476 blood stream infections, of which 15,183
(9.3%) were resistant to third-generation cephalosporins. An
estimated 5,503 excess deaths were associated with blood
stream infections caused by methicillin-resistant S. aureus
(with the UK and France predicted to experience the highest
excess mortality), and 2,712 excess deaths with blood stream
infections caused by third-generation cephalosporin-resistant
E. coli (predicted to be the highest in Turkey and the UK). The
researchers also found that blood stream infections caused by
both methicillin-resistant S. aureus and third-generation
cephalosporin-resistant E. coli contributed respective excesses
of 255,683 and 120,065 extra bed-days, accounting for an
estimated extra cost of 62.0 million Euros (92.8 million
international dollars). In their trend analysis, the researchers
found that 97,000 resistant blood stream infections and
17,000 associated deaths could be expected in 2015, along
with increases in the lengths of hospital stays and costs.
Importantly, the researchers estimated that in the near future,
the burden of disease associated with third-generation
cephalosporin-resistant E. coli is likely to surpass that
associated with methicillin-resistant S. aureus.
What Do These Findings Mean? These findings show that
even though the blood stream infections studied represent
only a fraction of the total burden of disease associated with
antibiotic resistance, excess mortality associated with these
infections caused by methicillin-resistant S. aureus and third-
generation cephalosporin-resistant E. coli is high, and the
associated prolonged length of stays in hospital imposes
a considerable burden on health care systems in Europe.
Importantly, a possible shift in the burden of antibiotic
resistance from Gram-positive to Gram-negative infections is
concerning. Such forecasts suggest that despite anticipated
gains in the control of methicillin-resistant S. aureus,t h e
increasing number of infections caused by third-generation
cephalosporin-resistant Gram-negative pathogens, such as
E. coli, is likely to outweigh this achievement soon. This
increasing burden will have a big impact on already stretched
health systems.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001104.
N The World Health Organization has a fact sheet on general
antimicrobial resistance
N The US Centers for Disease Control and Prevention
webpage on antibiotic/antimicrobial resistance includes
information on educational campaigns and resources
N The European Centre for Disease Control provides data
about the prevalence of resistance in Europe through an
interactive database
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